• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前瞻性评估半剂量光动力疗法与微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变后脉络膜血流指数的变化。

Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy.

机构信息

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.

Department of Ophthalmology, L.V. Prasad Eye Institute, Hyderabad, India.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2020 Jun;258(6):1191-1197. doi: 10.1007/s00417-020-04619-6. Epub 2020 Mar 13.

DOI:10.1007/s00417-020-04619-6
PMID:32170365
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7237528/
Abstract

PURPOSE

To assess whether treatment of chronic central serous chorioretinopathy (cCSC) with photodynamic therapy (PDT) and high-density subthreshold micropulse laser (HSML) results in choroidal vascularity index (CVI) changes that may account for the treatment effect.

METHODS

Patients with cCSC were prospectively included and analyzed. Patients received either half-dose PDT or HSML treatment. CVI of the affected and unaffected eye was obtained before treatment, 6 to 8 weeks after treatment, and 7 to 8 months after treatment.

RESULTS

At baseline, 29 eyes (29 patients) were included both in the PDT and in the HSML group. The mean (± standard deviation) CVI change in the HSML group between before PDT and 6 to 8 weeks after PDT was - 0.009 ± 0.032 (p = 0.127), whereas this was 0.0025 ± 0.037 (p = 0.723) between the visit before PDT and final visit. The patients in the PDT group had a CVI change of - 0.0025 ± 0.037 (p = 0.723) between the visit before PDT and first visit after PDT, and a mean CVI change of - 0.013 ± 0.038 (p = 0.080) between the visit before PDT and final visit. There was no significant correlation between CVI and BCVA at the measured time points, in both the HSML group (p = 0.885), and in the PDT group (p = 0.904). Moreover, no significant changes in CVI occurred in the unaffected eye at any time point.

CONCLUSIONS

PDT and HSML do not significantly affect CVI, and therefore a CVI change may not be primarily responsible for the treatment effect. The positive treatment effect of both interventions may rely on other mechanisms, such as an effect on choriocapillaris and/or retinal pigment epithelium function.

摘要

目的

评估慢性中心性浆液性脉络膜视网膜病变(cCSC)的光动力疗法(PDT)和高密度亚阈值微脉冲激光(HSML)治疗是否会引起脉络膜血管指数(CVI)的变化,而这些变化可能是治疗效果的原因。

方法

前瞻性纳入并分析了患有 cCSC 的患者。患者接受半剂量 PDT 或 HSML 治疗。在治疗前、治疗后 6-8 周和治疗后 7-8 个月获得受影响眼和未受影响眼的 CVI。

结果

在基线时,29 只眼(29 名患者)同时纳入 PDT 组和 HSML 组。HSML 组在 PDT 前和治疗后 6-8 周之间的 CVI 变化平均值(±标准差)为-0.009±0.032(p=0.127),而在 PDT 前就诊和最后就诊之间为 0.0025±0.037(p=0.723)。PDT 组患者在 PDT 前就诊和 PDT 后第一次就诊之间的 CVI 变化为-0.0025±0.037(p=0.723),在 PDT 前就诊和最后就诊之间的平均 CVI 变化为-0.013±0.038(p=0.080)。在 HSML 组(p=0.885)和 PDT 组(p=0.904),在测量的时间点,CVI 与 BCVA 之间均无显著相关性。此外,在任何时间点,未受影响眼的 CVI 均无显著变化。

结论

PDT 和 HSML 均不会显著影响 CVI,因此 CVI 变化可能不是治疗效果的主要原因。两种干预措施的积极治疗效果可能依赖于其他机制,例如对脉络膜毛细血管和/或视网膜色素上皮功能的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c4e/7237528/3f24d87e2aa3/417_2020_4619_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c4e/7237528/8ec179f82dc9/417_2020_4619_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c4e/7237528/3f24d87e2aa3/417_2020_4619_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c4e/7237528/8ec179f82dc9/417_2020_4619_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c4e/7237528/3f24d87e2aa3/417_2020_4619_Fig2_HTML.jpg

相似文献

1
Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy.前瞻性评估半剂量光动力疗法与微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变后脉络膜血流指数的变化。
Graefes Arch Clin Exp Ophthalmol. 2020 Jun;258(6):1191-1197. doi: 10.1007/s00417-020-04619-6. Epub 2020 Mar 13.
2
Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial.原发治疗失败后行光动力疗法或微脉冲激光光凝治疗慢性中心性浆液性脉络膜视网膜病变的随机对照研究(REPLACE 试验)。
Am J Ophthalmol. 2020 Aug;216:80-89. doi: 10.1016/j.ajo.2020.04.007. Epub 2020 Apr 11.
3
Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.半剂量光动力疗法联合二极管微脉冲激光疗法治疗慢性中心性浆液性脉络膜视网膜病变:一项前瞻性治疗方案的评估
Acta Ophthalmol. 2016 Mar;94(2):187-97. doi: 10.1111/aos.12938. Epub 2015 Dec 15.
4
Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.光动力疗法或微脉冲激光成功治疗慢性中心性浆液性脉络膜视网膜病变的长期随访。
Acta Ophthalmol. 2021 Nov;99(7):805-811. doi: 10.1111/aos.14775. Epub 2021 Feb 10.
5
RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4.脉络膜异常对光动力疗法与微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变的反应: 临床随机对照研究报告第 4 号。
Retina. 2021 Oct 1;41(10):2122-2131. doi: 10.1097/IAE.0000000000003157.
6
Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.半剂量光动力疗法或亚阈微脉冲激光治疗局灶性和弥漫性慢性中心性浆液性脉络膜视网膜病变:PLACETM 试验报告 3。
Am J Ophthalmol. 2019 Sep;205:1-10. doi: 10.1016/j.ajo.2019.03.025. Epub 2019 Apr 3.
7
Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.半剂量光动力疗法与高密度亚阈值微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变患者:PLACE 试验。
Ophthalmology. 2018 Oct;125(10):1547-1555. doi: 10.1016/j.ophtha.2018.04.021. Epub 2018 Jun 14.
8
Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.黄色(577nm)微脉冲激光与半剂量维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变:泛美合作视网膜研究(PACORES)组的结果。
Br J Ophthalmol. 2018 Dec;102(12):1696-1700. doi: 10.1136/bjophthalmol-2017-311291. Epub 2018 Feb 8.
9
Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.慢性中心性浆液性脉络膜视网膜病变的视网膜下液形态及其与治疗的关系:PLACETM 试验数据的回顾性分析。
Acta Ophthalmol. 2022 Feb;100(1):89-95. doi: 10.1111/aos.14901. Epub 2021 May 16.
10
Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.聚焦式与传统维替泊芬光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变的比较
Korean J Ophthalmol. 2019 Dec;33(6):506-513. doi: 10.3341/kjo.2019.0065.

引用本文的文献

1
Capturing the transition from intermediate to neovascular AMD: Longitudinal changes in choroidal volume and choroidal vascularity index.捕捉中间型到新生血管性年龄相关性黄斑变性的转变:脉络膜体积和脉络膜血管指数的纵向变化。
Graefes Arch Clin Exp Ophthalmol. 2025 Feb 13. doi: 10.1007/s00417-025-06767-z.
2
Long-term effect of photodynamic therapy on choroidal vascularity index versus choroidal thickness as biomarkers for chronic central serous chorioretinopathy.光动力疗法对脉络膜血管指数与脉络膜厚度的长期影响作为慢性中心性浆液性脉络膜视网膜病变的生物标志物
Eye (Lond). 2025 Apr;39(6):1183-1192. doi: 10.1038/s41433-024-03571-7. Epub 2025 Jan 6.
3

本文引用的文献

1
Central serous chorioretinopathy: Towards an evidence-based treatment guideline.中心性浆液性脉络膜视网膜病变:迈向基于证据的治疗指南。
Prog Retin Eye Res. 2019 Nov;73:100770. doi: 10.1016/j.preteyeres.2019.07.003. Epub 2019 Jul 15.
2
Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.半剂量光动力疗法或亚阈微脉冲激光治疗局灶性和弥漫性慢性中心性浆液性脉络膜视网膜病变:PLACETM 试验报告 3。
Am J Ophthalmol. 2019 Sep;205:1-10. doi: 10.1016/j.ajo.2019.03.025. Epub 2019 Apr 3.
3
Changes in Stromal and Luminal Areas of the Choroid in Pachychoroid Diseases: Insights Into the Pathophysiology of Pachychoroid Diseases.
Fluorescein angiography patterns and subretinal hyperreflective material predict subthreshold micropulse laser response in chronic central serous chorioretinopathy.
荧光素血管造影模式和视网膜下高反射物质预测慢性中心性浆液性脉络膜视网膜病变中阈下微脉冲激光的反应。
BMC Ophthalmol. 2024 Nov 4;24(1):478. doi: 10.1186/s12886-024-03711-3.
4
CHOROIDAL VASCULARITY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AND ITS ASSOCIATION WITH RISK SINGLE-NUCLEOTIDE POLYMORPHISMS.慢性中心性浆液性脉络膜视网膜病变中的脉络膜血管性及其与风险单核苷酸多态性的关联
Retina. 2024 May 1;44(5):837-843. doi: 10.1097/IAE.0000000000004024. Epub 2024 Apr 18.
5
Postoperative Choroidal Vascular Biomarkers in Eyes with Rhegmatogenous Retinal Detachment-Related Giant Retinal Tears.孔源性视网膜脱离相关巨大视网膜裂孔眼术后脉络膜血管生物标志物
Int J Retina Vitreous. 2023 Aug 1;9(1):45. doi: 10.1186/s40942-023-00482-9.
6
Continuous Eplerenone Treatment in Chronic Central Serous Chorioretinopathy: Long-Term Results from a Pilot Study.依普利酮持续治疗慢性中心性浆液性脉络膜视网膜病变:一项试点研究的长期结果
Clin Ophthalmol. 2023 Jul 17;17:2003-2012. doi: 10.2147/OPTH.S411094. eCollection 2023.
7
Randomized controlled trials in central serous chorioretinopathy: A review.随机对照试验在中心性浆液性脉络膜视网膜病变中的应用:综述。
Eye (Lond). 2023 Nov;37(16):3306-3312. doi: 10.1038/s41433-023-02509-9. Epub 2023 Mar 30.
8
Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature.黄色阈下微脉冲激光治疗视网膜疾病:文献的深入分析与综述
Ophthalmol Ther. 2023 Jun;12(3):1479-1500. doi: 10.1007/s40123-023-00698-w. Epub 2023 Mar 18.
9
Comparing treatment outcomes in randomized controlled trials of central serous chorioretinopathy.比较中心性浆液性脉络膜视网膜病变随机对照试验的治疗结果。
Graefes Arch Clin Exp Ophthalmol. 2023 Aug;261(8):2135-2168. doi: 10.1007/s00417-023-05996-4. Epub 2023 Mar 2.
10
Wide-field OCT-angiography assessment of choroidal thickness and choriocapillaris in eyes with central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变患者脉络膜厚度和脉络膜毛细血管的超广角光学相干断层扫描血管造影评估
Front Physiol. 2022 Oct 21;13:1008038. doi: 10.3389/fphys.2022.1008038. eCollection 2022.
脉络膜增厚性疾病中脉络膜基质和管腔面积的变化:对脉络膜增厚性疾病发病机制的深入了解。
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):4896-4908. doi: 10.1167/iovs.18-25018.
4
Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.半剂量光动力疗法与高密度亚阈值微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变患者:PLACE 试验。
Ophthalmology. 2018 Oct;125(10):1547-1555. doi: 10.1016/j.ophtha.2018.04.021. Epub 2018 Jun 14.
5
Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.对低剂量光动力疗法反应不足的慢性中心性浆液性脉络膜视网膜病变患者的临床特征
Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1395-1402. doi: 10.1007/s00417-018-4003-z. Epub 2018 May 7.
6
Quantitative shadow compensated optical coherence tomography of choroidal vasculature.脉络膜血管的定量阴影补偿光相干断层扫描。
Sci Rep. 2018 Apr 24;8(1):6461. doi: 10.1038/s41598-018-24577-8.
7
Influence of scanning area on choroidal vascularity index measurement using optical coherence tomography.扫描区域对使用光学相干断层扫描测量脉络膜血管指数的影响。
Acta Ophthalmol. 2017 Dec;95(8):e770-e775. doi: 10.1111/aos.13442. Epub 2017 May 4.
8
Preferred practice pattern in central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变的首选治疗模式。
Br J Ophthalmol. 2017 May;101(5):587-590. doi: 10.1136/bjophthalmol-2016-309247. Epub 2016 Aug 18.
9
Automated estimation of choroidal thickness distribution and volume based on OCT images of posterior visual section.基于后节段 OCT 图像的脉络膜厚度分布和体积的自动估算。
Comput Med Imaging Graph. 2015 Dec;46 Pt 3:315-27. doi: 10.1016/j.compmedimag.2015.09.008. Epub 2015 Oct 22.
10
Oral eplerenone for the management of chronic central serous chorioretinopathy.口服依普利酮治疗慢性中心性浆液性脉络膜视网膜病变
Int J Ophthalmol. 2015 Apr 18;8(2):310-4. doi: 10.3980/j.issn.2222-3959.2015.02.17. eCollection 2015.